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Abstract
Program death receptor-1 (PD-1) is upregulated in many tumors and in tumor microenvironment, and PD-1
blockade has led to remarkable immune-based anti-tumor responses in across many tumor types. Pembrolizumab,
an anti-programmed death 1 checkpoint inhibitor, resulted in a high rate of immune response in 41 patients with
previously treated mismatch repair (MMR)-deficient tumor including colorectal cancer but not in MMR-stable tumor
with expectant toxicities. Both immune-based progression-free and overall survival are quite promising and
correlate with high mutation loads in the tumor. MMR-deficient tumors made up not an insignificant proportion of
GI and GU cancers and are found mostly in younger patients who had better prognosis than MMR-stable tumors.
However, MMR-deficient tumors do not respond to cytotoxic chemotherapy as these agents may require intact
DNA mismatch repair to be effective. MMR deficiency occurred as a result of mutations in defined DNA repair complex
mutations or epigenetics modifications and gene upstream of DNA repair complex. PD-1 blockade represents our first
successful shot at one of the Achilles heels of this MMR-deficient tumor goliath. Only coordinated attack on all of its
Achilles heels and healing mechanisms can this tumor Goliath be brought down to its knees.
Program death receptor-1 (PD-1) is upregulated in many
tumors and in their surrounding microenvironment, and
blockade of these immune checkpoints with anti-PD-1
monoclonal antibodies has led to remarkable clinical
responses in melanomas, non-small-cell lung cancer,
renal-cell carcinoma, bladder cancer, and Hodgkin’s
lymphoma [1–3]. High numbers of somatic mutations in
lung cancer due to cigarette smoke and in melanoma
due to ultraviolet radiation correlated with response to
PD-1 blockade but not PD-1 expression [4]. Correlation
of immune to the tumor mutation load was first noted
with CTLA blockade in melanoma [5]. DNA mismatch
repair machinery is essential in governing the genomic
integrity, and loss of DNA mismatch repair function com-
plex can occur either at the germ-line level or at the epi-
genetic level summarized elsewhere [6]. Mismatch repair
plays a central role in maintaining genomic stability by
repairing DNA replication errors and inhibiting recombin-
ation between non-identical (homologous) sequences [7].
Dr. Le and Diaz group conducted a pivotal phase II study
on pembrolizumab (KEYTRUDA), an anti-programmed
death 1 checkpoint inhibitor, in 41 patients with previ-
ously treated progressive metastatic carcinoma with or
without mismatch repair deficiency. This phase 2 study
administered pembrolizumab (10 mg/kg every 2 weeks).
Three groups were evaluated: mismatch repair (MMR)-
deficient colorectal cancer (n = 13), MMR-proficient colo-
rectal cancer (n = 25), and MMR-deficient other cancers
(n = 10). Mismatch repair status was assessed using a
standard polymerase chain reaction (PCR)-based method
for detection of microsatellite instability. The primary
endpoints of the study were immune-related progression-
free survival (PFS) rate as assessed at 20 weeks and overall
response rate; secondary endpoints included overall
survival (OS) and progression-free survival (as measured
by RECIST v1.1) and disease control rate.
Despite the prior chemotherapy with some patients
receiving up to four lines of chemotherapy, pembrolizumab
resulted in response rate, progression-free survival, and
overall survival for a diverse group of MMR-deficient
cancers, but not in MMR-stable cancers [8]. The immune-
related objective response rate and immune-related
progression-free survival rate were 40 % (4 of 10 patients)
and 78 % (7 of 9 patients), respectively, for mismatch
repair-deficient colorectal cancers and 0 % (0 of 18
* Correspondence: elin@p4mi.org
2P4 Medicine Institute, Seattle Cancer Care Alliance, Fred Hutchinson Cancer
Research Center, University of Washington Medical Center, Seattle, WA
98109, USA
Full list of author information is available at the end of the article
JOURNAL OF HEMATOLOGY
& ONCOLOGY
© 2015 Lin and Lin. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lin and Lin Journal of Hematology & Oncology  (2015) 8:124 
DOI 10.1186/s13045-015-0222-5
patients) and 11 % (2 of 18 patients), respectively, for
mismatch repair-proficient colorectal cancers. The median
progression-free survival and overall survival were not
reached in the cohort with mismatch repair-deficient colo-
rectal cancer but were 2.2 and 5.0 months, respectively, in
the cohort with mismatch repair-proficient colorectal
cancer (hazard ratio for disease progression or death, 0.10
(P < 0.001), and hazard ratio for death, 0.22 (P = 0.05)).
Patients with mismatch repair-deficient non-colorectal
cancer had responses similar to those of patients with mis-
match repair-deficient colorectal cancer (immune-related
objective response rate, 71 % (5 of 7 patients); immune-
related progression-free survival rate, 67 % (4 of 6
patients)). Whole-exome sequencing revealed a mean of
1782 somatic mutations per tumor in mismatch repair-de-
ficient tumors, as compared with 73 in mismatch repair-
proficient tumors (P = 0.007), and high somatic mutation
loads were associated with prolonged progression-free
survival (P = 0.02). The most common treatment-related
adverse events (occurring in greater than or equal to 10 %
of patients) included rash/pruritus (17 %), pancreatitis
(15 %), and thyroiditis/hypothyroidism (10 %). Grades 3–4
treatment-related adverse events were rare occurring in
2 % of patients (N = 1). This seminal work confirmed the
earlier observation that only 1 of 33 patients with colorec-
tal cancer with MMR deficiency responded to pembrolizu-
mab and higher mutation loads (up to 20-fold) found in
MMR-deficient tumors correlated with both immune-
based response and improved progression-free survival to
PD-1 blockade [8]. Increased mutations loads in the
MMR-deficient tumors lead to increased neo-antigens
which serve as a biomarker in cancer immunotherapy and
as novel therapeutic tumor vaccine to selectively enhance
T cell across different tumor types [9]. Membranous PDL-
1 expressions were noted in all MMR-deficient tumors and
correlate with the presence of CD8 cells but fail to predict
in vivo immune response, progression, or survival in this
small study. Based on this promising study, two studies
sponsored by Merck were launched including KEYNOTE-
164: a phase II study of pembrolizumab (MK-3475) as
monotherapy in subjects with previously treated locally ad-
vanced unresectable or metastatic (stage IV) mismatched
repair-deficient or microsatellite instability-high colorectal
carcinoma (NCT02460198) and CheckMate 142 study of
nivolumab and nivolumab plus ipilimumab in recurrent
and metastatic colon cancer (NCT02060188).
Anti-PD-1 therapy will become the first immune ther-
apy backbones for these MMR-deficient tumor patients
whose median age is in their 40s as opposed to 60s in
patients with MMR-proficient tumors [7, 10]. MMR
deficiency is commonly found across a spectrum of
cancers: uterus (~30 %), stomach (9 %), colorectum
(15 %), ampulla of biliary tract (9 %) [11], acinar gland
of the pancreas (14 %) [12], ovary (10–30 %) [13, 14],
prostate (19 %) and small intestine (23 %) as well as in
breast cancer (5 %) [15]. Mismatch repair-deficient
tumor microenvironment strongly expressed several im-
mune checkpoint ligands, including PD-1, PDL1, CTLA-
4, LAG-3, and IDO, which indicates that their active
immune microenvironment is counterbalanced by im-
mune inhibitory signals that resist tumor elimination. As
compared to MMR-stable tumors, MMR-deficient can-
cers of colorectum [16], small intestine [17], acinar gland
of the pancreas [12], stomach, ampulla [11], prostate
[18], and ovary [14], except for uterine cancer [19, 20],
are associated with improved survival [21]. Increased im-
mune surveillance in MMR deficiency in the tumors
may in fact explain the pattern of earlier stage presenta-
tion, lack of lymph node metastasis (stage II in colon
cancer), and restored immune suppression following pri-
mary tumor resection. MMR-deficient tumors enjoyed
infiltration of cytotoxic T cells in both the tumor and
the close border around the tumor, as well as increased
intra-epithelial infiltration with higher angiogenic cap-
acity [22]. A low intra-epithelial CD3(+)/FoxP3(+) cell
ratio predicted reduced DFS 46.2 vs 66.7 % survival at
5 years [16].
MMR deficiency (or microsatellite instability) is noted
in both hereditary tumors as well as in sporadic tumors
due germ-line mutations or aberrant methylation of pro-
moter region CpG islands in the MMR genes [7]. Genes
upstream of regulating MSH2 degradation, i.e., FRAP1
(also known as MTOR) HERC1, PRKCZ, and PIK3C2B,
can also lead to undetectable levels of MSH2 protein
and MSI instability. Even though, RFC, PCNA, POLδ,
and RPA are essential parts of DNA repair machinery
and their defects could be lethal to living cells. However,
POLδ variant, POLε variant, or MYH could also lead to
MMR deficiency phenotype. Of MMR DNA repair com-
plex, MLH1 and MSH2 are dominant players in safe-
guarding the genome from promiscuous recombination
and their defect leads to complete loss of mismatch re-
pair function whereas MSH6, MLH2, MSH3, and PMS1
are relatively redundant and exert weaker effects. MMR
complex interacts with pivotal genes such as p53, c-Abl,
and p73 regulating mismatch repair-dependent apoptosis
pathway, transcriptional regulation, signaling transduc-
tion, DNA repair, immune surveillance, and drug resist-
ance (Fig. 1) [6, 23–25]. Methylated p14 is associated
with the presence of microsatellite instability and with
the absence of p53 mutations. The impact of other gen-
etic mutations on MMR could impact effects of chemo-
therapy as well as immune response. Mutations in both
alleles of the hMLH1 gene are necessary for the mani-
festation of defective mismatch repair. There are 100
times more mutation loads in the MMR-deficient tu-
mors than in the MSI-stable tumors. MSI phenotype
testing by the current IHC or PCR methods may not
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reveal the full spectrum of high mutation load tumors
suitable for therapy with anti-PD-1 blockade. Combining
MSI testing and mutation load through next generation
sequencing (NGS) may further expand the eligible
patient pool for anti-PD-1-based therapy and multi-
tumor basket trial.
Pembrolizumab resulted in immune-based response in
high mutation load MMR-deficient tumors and moder-
ate overall survival than in MMS-stable tumors. However,
the progression-free survival and overall survival gain
remain modest in this small pilot study. To bring down
the tumor giant, PD-1 may be one of the Achilles heels of
tumor to target. Immune editing, clonal T cells repertoire
deletions, and strong immunosuppressive microenviron-
ment are some of the underlying mechanisms for non-
responders to PD-1 blockade. There are complex interplay
between the tumor, the supporting tumor microenviron-
ment, and the immune system at both the local and
systemic levels contributing to tumor regression as well as
progression. Combination immune checkpoint inhibitors
including PD-1, PDL-1 LAG-3, OX40, and IDO may
provide additional boost in immune response against the
tumor as well as increase in toxicities. In addition, PD-1
checkpoint inhibitor may be combined with tumor-
specific T (CAR-T) and NK cells with or without dendritic
cells and tumor vaccines for priming. Another approach is
to suppress cytotoxic T suppressor and myeloid-derived
suppressor cells (MDSC). Recently, we had witnessed a pro-
gress using unique structure of chimeric antigen receptor
(CAR)-endows T cell tumor conferring specific cytotoxicity
and resistance to immunosuppressive microenvironment in
cancers. Challenges remain before widespread clinical ap-
plication especially if one were to combine that with add-
itional checkpoint inhibitors. Re-engineered NK cells may
hold certain advantages over T cells, and synergy with PD-
1/PDL-1 blockade will need to be explored also in the fu-
ture [26]. One will also need to figure out how to combine
or sequence standard first-line cytotoxic chemotherapy
and/or targeted therapy with checkpoint inhibitor in the
MMR-deficient tumors. Alkylating agent requires an
intact DNA mismatch repair mechanism to cause
DNA double-strand breaks to lead to tumor cell apop-
tosis and mediate certain resistance to cytotoxic agents
[23–25]. Combine or sequence standard first-line cyto-
toxic chemotherapy and/or targeted therapy with check-
point inhibitor in the MMR-deficient tumors. Both TS
and DPD (5FU resistance genes) are overexpressed in
MMR-deficient tumors as compared with MMR-
proficient tumors explaining the relative drug resistance
of MMR-deficient tumors to 5FU-based therapy. Muta-
tions type II receptor for TGF-beta1 with high levels of
microsatellite instability point to a favorable outcome to
fluorouracil-based adjuvant regimens for stage II and stage
III colon cancer [27]. B-raf mutation is linked to the
MMR deficiency of these tumors in repairing mismatched
bases in DNA and is associated with poor prognosis in
colorectal cancer [28]. One direction is to explore B-raf
inhibition in combination with immune checkpoint inhib-
ition, but the sequencing and secondary pathways per-
turbed by B-raf mutation inhibition will need to be
understood [29]. Other option is to explore MEK and in-
hibitor can also be explored in combination therapy [30].
Fig. 1 Microsatellite instability is central in colorectal cancer carcinogenesis in both hereditary nonpolyposis syndrome and sporadic colorectal cancer
through germ-line mutations in MMR genes or by hMLH-1 DNA methylation in the CIMP-H, respectively. Microsatellite instability affects DNA repair,
transcription regulation, signaling, and apoptosis
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For non-colorectal cancer, many of the tumor utilizes plat-
inum based or 5FU-based regimen and integrating PD-1
blockade in these tumors will require careful understand-
ing of the tumor response characteristics, sequencing, and
tumor heterogeneity. Thus, first-line treatment with agents
that deplete or inhibit key immune-suppressing stroma
molecules and that provide co-stimulatory support, treat-
ment using vaccines that induce an immune response in
non-immunogenic cancers, or a combination of these
agents should be the first step toward recruiting activated
T cells into the tumor.
In summary, enhanced efficacies without systemic tox-
icities are the primary goals of anti-cancer therapy
including immunotherapy. Major therapeutic gains have
been made in a wide variety of solid tumors by blocking
programmed death-1/programmed death ligand-1 (PD-1/
PD-L1) pathways. The mechanisms of anti-PD-1/PDL-1
blockade differ from other immunotherapeutic approaches
in that it leads to more tumor-specific immune modulation
by targeting tumor-induced immune defects and by repair-
ing ongoing tumor immunity instead of de novo immunity
using other approaches, e.g., CAR-T. We will need more
reliable biomarkers to predict, recognize, monitor, define,
and grade immune-mediated adverse events as well as
response across all tumor types and tissues and organs in
light of the observation that we see increasing toxicities in
GI, liver function, and endocrine abnormalities from treat-
ment especially combination treatment strategies which is
the way of the future [31]. Success of anti-PD-1/PDL1 has
already set a very higher bar for future innovations to excel
in more efficacious and less toxicities in all human tumors.
Now, this tumor Goliath is in the open fields and PD-1
blockade represents its first successful shot at its Achilles
heel; however, much of the work remains in order to bring
down this tumor Goliath to its knees by targeting other
unexposed Achilles heels and its healing mechanisms.
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